Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We expect strong Pega product sales to continue into 2024 and likely 2025, as we deploy inventory and train our sales channel |
| Overall, we've got a really nice setup for our international business and we believe that 2024 will show great improvement beginning as early as Q1 |
| Am I hearing you correctly, Dave? David Bailey Yes, I think that we are another quarter into this improvement and I think we're seeing that improvement here in Q1 as well |
| This continues to be the most important metric of success for OrthoPediatrics, and each year we strive to increase our impact and benefit more kids |
| So until we see that, June, July and August, I don't know that we're going to declare victory, but it's certainly encouraging,that we're seeing this come through |
| We are in an extremely strong position with all the tools in place to help more children than ever before |
| Driven by favorable leverage in the cash portion of G&A, disciplined expense management, strong margins and healthy revenue growth |
| We are excited to report that we outperformed our original adjusted EBITDA expectations, producing a record adjusted EBITDA of $5 million in 2023 |
| In addition, we're thrilled to see our prior acquisitions fully integrated and performing well with robust top line revenue contributions and profitability |
| Looking closer at the quarter, revenue and surgery scheduling was strong throughout, except during the final two weeks of December, when we started to experience lighter surgical volumes due to an uptick in RSV |
| So yes, that's obviously why we're one of the reasons why we think we should be pretty excited about the opportunity here |
| All of our long-term plans, including profitability growth are supported by our robust balance sheet, strong cash position and access to debt |
| Altogether, volumes and staffing continue to improve month-over-month and while still not running full tilt we are encouraged recovery in the environment is tracking our expectations for modest sequential improvement |
| The diverse nature of our business continued to benefit OrthoPediatrics in the quarter |
| The global trauma and deformity, domestic scoliosis and OPSB business were very strong, offset by lower growth in international scoliosis |
| Fourth quarter global T&D was very strong at 23% with growth led by sales of Pega products, PNP Femur, early sales of PNP Tibia and growth within the OPSB franchise |
| This combined with the launch and the growth of the OPSB franchise ensure we can maintain our high rate of growth while using less cash for inventory deployment, thus ensuring we drive to cash flow breakeven much sooner than earlier anticipated |
| We continue to expect strong performance from our legacy products as a result of our heavy investment in set deployments in 2022 and 2023 |
| With multiple opportunities including continuing legacy product growth, several key new organic product launches, Pega sales expansion, normalization of international markets, positive longer term ApiFix data publications, a newly formed and rapidly expanding specialty bracing business OPSB and an early start in digital healthcare |
| We are confident in our growth prospects for 2024 and beyond |
| Importantly, we remain in an extremely secure financial position and are confident that our current balance sheet enables us to execute our long-term strategy without additional equity capital |
| It is positive adjusted EBITDA, it's positive net income, positive cash flow |
| We achieved a record number of children helped, record revenue and generated record adjusted EBITDA |
| We continue to balance top line revenue growth with improved profitability on our way to cash flow break even sooner, a trend we expect to carry into 2024 |
| We expect positive trends in the business to continue, including robust top line revenue growth and continued profitability growth as we move toward cash flow breakeven earlier than anticipated |
| Strong performances from Pega products, trauma, Ex-Fix and OPSB, led revenue growth in the quarter |
| We saw continued record Pega product performance with substantial growth of 59% in the U.S |
| Sales with Pega continued to be better than we ever expected and as we more deeply penetrate our U.S |
| As we look back on 2023, we're proud of all that we've achieved and are confident that we have the right growth drivers in place for continued success in 2024 |
| But I think at this stage, we feel good about that being behind us and being able to diversify our scoliosis business now that we're in markets like Canada, and the rest of Europe |
| Statement |
|---|
| Children's hospitals, very limited competition, a general lack of ongoing innovation and the opportunity to provide elite level of customer service and support clinical education and training |
| Overall, global scoliosis growth was slightly muted by a continuation of slower than expected ordering in our Latin and South American business, resulting in a 31% reduction in OUS scoliosis sales and negatively impacting overall growth |
| Fourth quarter international sales declined by 31% and were lighter due to continued chopping ordering patterns from a few large international stocking distributors in Latin and South America |
| And it was disappointing to see |
| And so if you think about the legacy business in those factors, the first quarter revenue would come down |
| When you look at the lower sales to stocking distributors in South America, maybe the lower than expected orders in Latin and South America |
| growth of 35%, partially offset by canceled cases in late December from RSV and lower than expected orders in Latin and South America |
| It was a pretty big headwind on the scolio growth overall and on the company's growth overall |
| And it was a bit bit unfortunate, but not a lot we can do about it |
| Overall, we feel this headwind is lessening and we will remain cautious until we see further normalization |
| A little lower in the second quarter, come down again in the fourth quarter and a little softer in the first quarter |
| We're a little cautious just because we recognize that June, July, August, these are our, obviously our big months on the surgical side |
| The first quarter is typically around 5% or 6% lower than the fourth quarter |
| This compares to a loss of $2.2 million in the fourth quarter of 2022 |
| I've been with OP for nearly 17 years now and I'm not sure I've ever been more excited |
| So traditionally, pre-COVID in particular, because the last several years have been so unusual |
| So that is a possibility |
| And so, I think that's why you hear fairly bullish commentary about the way the hospitals are handling the RSV situation, how rapidly it went up, affected us and came back down here in the first quarter |
| The slight increase in gross profit margin was driven primarily by lower set sales to international stocking distributors |
| But I think as we model, as we guide, we're not going to get ahead of ourselves here |
Please consider a small donation if you think this website provides you with relevant information